Lifecore Biomedical shareholders approve issuance of shares beyond 19.99% threshold

LIFECORE BIOMEDICAL, INC. DE

At April 10, 2025 special meeting, stockholders approved the Issuance Proposal, allowing issuance of common stock underlying Series A Preferred Stock in excess of 19.99% of outstanding common shares.
Votes on Issuance Proposal: 24,098,218 For, 444,639 Against, 33,281 Abstain.
Adjournment Proposal was also approved (28,882,501 For) but not needed since Issuance Proposal passed.
The approval relates to the Securities Purchase Agreement dated January 9, 2023, with named investors.

item 5.07

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001005286-25-000061
form_type: 8-K
ticker: LFCR
cik: 0001005286
company_name: LIFECORE BIOMEDICAL, INC. DE
filed_at: 2025-04-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:47.134461+00:00
generated_at: 2026-05-23T16:46:24.967578+00:00
sec_items: ["5.07"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001005286-25-000061
json_url: https://secwatch.observer/filing/0001005286-25-000061.json
markdown_url: https://secwatch.observer/filing/0001005286-25-000061.md
text_url: https://secwatch.observer/filing/0001005286-25-000061.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000061/0001005286-25-000061-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000061/lndc-20250410.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001005286-25-000061

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.